Posdinemab

The FDA granted priority review to Johnson & Johnson's nipocalimab for treating generalized myasthenia gravis (gMG) in antibody-positive patients, based on Phase III Vivacity-MG3 study data.

Johnson & Johnson's posdinemab, a monoclonal antibody targeting phosphorylated tau, has received FDA Fast Track designation for early Alzheimer's treatment.

The FDA granted breakthrough therapy designation to STK-001 for Dravet syndrome, highlighting its potential to improve upon current treatments by restoring NaV1.1 protein levels.

Johnson & Johnson Innovative Medicine is developing JNJ-2056, a novel liposomal vaccine targeting phospho-Tau (pTau) for the treatment of Alzheimer's disease and other tauopathies.

AC Immune's Q3 2024 was marked by advancements in its ACI-7104.056 VacSYn Phase 2 trial for Parkinson's disease and a CHF 24.6 million milestone payment in an Alzheimer's Phase 2b trial.